Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

NovaBay Pharmaceuticals And Sonoma Pharmaceuticals Agree To Market Avenova-Branded Products In European Union; Sonoma Will Manufacture Ocudox And Pay NovaBay Royalty Fee Based On Net Product Sales

Author: Benzinga Newsdesk | January 09, 2024 10:18am

The new products will combine Sonoma's existing eye product Ocudox®, which has already received a Class IIB CE mark for sale in the European Union, with Avenova branding, and are expected to be marketed through Sonoma's established European distribution network. This agreement brings together NovaBay's deep knowledge of eye care reflected in its Avenova brand with Sonoma's expertise in distributing hypochlorous acid products overseas.

Posted In: NBY SNOA


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist